We have located links that may give you full text access.
Association of Ischemic Imaging Phenotype With Progression of Brain Atrophy and Cerebrovascular Lesions on MRI: The SMART-MR Study.
Neurology 2021 July 22
OBJECTIVE: To investigate the association of silent vascular lesions, imaging negative ischemia, and symptomatic cerebrovascular disease with long-term progression of brain atrophy and cerebrovascular lesions in patients with arterial disease.
METHODS: Within the SMART-MR study, stroke status of participants at baseline was classified as no cerebrovascular disease (reference group, n=829), symptomatic cerebrovascular disease (n=206), silent vascular lesion (n=157), and imaging negative ischemia (n=90) based upon clinical and MRI findings. Using linear mixed models, changes in brain and white matter hyperintensity (WMH) volumes at baseline and during 12 years of follow-up were studied in stroke classifications. Relative risks were estimated for new infarcts during follow-up associated with stroke classifications. Analyses were adjusted for age, sex, cardiovascular risk factors, and medications.
RESULTS: Symptomatic cerebrovascular disease associated with 0.35 SDs (95%CI 0.24-0.47) smaller brain volume and 0.61 SDs (95%CI 0.48-0.74) larger WMH volume at baseline, and increased risk for new infarcts during follow-up (risk ratio (RR) 2.89; 95%CI 2.00-4.16). Silent vascular lesions associated with 0.15 SDs (95%CI 0.01-0.88) smaller brain volume, 0.02 SDs (95%CI 0.01-0.03) steeper brain atrophy slope, and 0.48 SDs (95%CI 0.32-0.64) larger WMH volume at baseline, in addition to increased risk for lacunes (RR 2.08; 95%CI 1.48-2.94). Individuals with imaging negative ischemia had increased risk for cortical infarcts (RR=2.88; 95%CI 2.17-3.82).
CONCLUSIONS: Patients with symptomatic cerebrovascular disease, silent vascular lesions, or imaging negative ischemia have different course of brain volume loss and cerebrovascular lesions development. These findings may have implications for future stroke risk and dementia and need further investigation.
METHODS: Within the SMART-MR study, stroke status of participants at baseline was classified as no cerebrovascular disease (reference group, n=829), symptomatic cerebrovascular disease (n=206), silent vascular lesion (n=157), and imaging negative ischemia (n=90) based upon clinical and MRI findings. Using linear mixed models, changes in brain and white matter hyperintensity (WMH) volumes at baseline and during 12 years of follow-up were studied in stroke classifications. Relative risks were estimated for new infarcts during follow-up associated with stroke classifications. Analyses were adjusted for age, sex, cardiovascular risk factors, and medications.
RESULTS: Symptomatic cerebrovascular disease associated with 0.35 SDs (95%CI 0.24-0.47) smaller brain volume and 0.61 SDs (95%CI 0.48-0.74) larger WMH volume at baseline, and increased risk for new infarcts during follow-up (risk ratio (RR) 2.89; 95%CI 2.00-4.16). Silent vascular lesions associated with 0.15 SDs (95%CI 0.01-0.88) smaller brain volume, 0.02 SDs (95%CI 0.01-0.03) steeper brain atrophy slope, and 0.48 SDs (95%CI 0.32-0.64) larger WMH volume at baseline, in addition to increased risk for lacunes (RR 2.08; 95%CI 1.48-2.94). Individuals with imaging negative ischemia had increased risk for cortical infarcts (RR=2.88; 95%CI 2.17-3.82).
CONCLUSIONS: Patients with symptomatic cerebrovascular disease, silent vascular lesions, or imaging negative ischemia have different course of brain volume loss and cerebrovascular lesions development. These findings may have implications for future stroke risk and dementia and need further investigation.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app